Complete Regression of Cutaneous Metastases With Systemic Immune Response in a Patient With Triple Negative Breast Cancer Receiving P53MVA Vaccine With Pembrolizumab

OncoImmunology - United States
doi 10.1080/2162402x.2017.1363138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy

Clinical Breast Cancer
Cancer ResearchOncology
2013English

A microRNA Signature Associated With Pathological Complete Response to Novel Neoadjuvant Therapy Regimen in Triple-Negative Breast Cancer

Tumor Biology
MedicineCancer Research
2017English

Systemic Inflammatory Response Syndrome in a Patient Diagnosed With High Grade Inflammatory Triple Negative Breast Cancer: A Case Report of a Potentially Rare Paraneoplastic Syndrome

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2015English

Development of a Vaccine Targeting Triple-Negative Breast Cancer

2013English

The WNT10B Network Is Associated With Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Cancer Research
Cancer ResearchOncology
2018English

PIK3CA H1047R Mutation Associated With a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated With Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2020English

Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides

JAMA Dermatology
DermatologyMedicine
2016English

Brachyury, a Vaccine Target, Is Overexpressed in Triple-Negative Breast Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2016English

CIP4 Promotes Metastasis in Triple-Negative Breast Cancer and Is Associated With Poor Patient Prognosis

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy